IPX203 shows sustained safety, efficacy in RISE-PD extension trial
Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a sustained control of symptoms for Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from the nine-month extension study (NCT03877510) indicate dose adjustments and side effects were…